While attendees of the annual JPMorgan H&Q Healthcare Conference scurried through the hallways of the Westin St. Francis hotel here, transgenic mouse company Medarex Inc. let loose a box full of news, including a three-way deal against breast cancer that is the fulfillment of the original promise of genomics and proteomics to turn target discovery into product development, said Donald Drakeman, president and CEO.